Employee Retention Tax Credit Application Deadline & Eligibility Report Launched

Oct 19, 2023

Summary

ERTC Guy has released a new report that provides information on the deadlines for pandemic relief claims from 2020 and 2021, as well as guidance on how employers can maximize their rebates. The report explains the eligibility requirements and changes to the guidelines for the Employee Retention Tax Credit (ERTC), which offers rebates to employers who kept staff on the payroll during the pandemic. The program has no upper limit on funding, allowing some employers to claim upwards of $750,000. The report also highlights that there is still billions of dollars left to be claimed through the ERTC program.

To determine eligibility and potential rebate amounts, employers are encouraged to complete a no-cost eligibility assessment on the ERTC Guy website, which asks 10 simple questions and requires no proprietary business information. The assessment is open to any employer with fewer than 500 W-2 employees on the payroll during the pandemic, including startups, new businesses, and non-profit organizations. Employers who have already received Paycheck Protection Program (PPP) loans are also encouraged to apply for ERTC rebates.

For more information about the ERTC program, upcoming deadlines, and the eligibility assessment, visit the ERTC Guy website.

This new ERTC funding report explores the deadlines for pandemic relief claims from 2020 and 2021, and how employers can maximize their rebates. The specialists at ERTC Guy have also launched a no-cost eligibility assessment, which provides fast refund estimates with no obligation.

New York, United States - October 19, 2023 /PressCable/

Employers that kept staff on the payroll during the recent pandemic must submit their applications soon to qualify for Employee Retention Tax Credit (ERTC) rebates before the deadline. This new specialist report launched by ERTC Guy explains the upcoming deadlines, eligibility requirements, and how employers can maximize their rebates.

More information about upcoming application deadlines, changes to the eligibility guidelines, and the maximum rebates for small businesses can be found at https://ertcguy.com/employee-retention-tax-credit-extension/

This new specialist report explains in detail how employers can qualify for and claim ERTC rebates, even if they were previously disqualified for having too many employees, operating the wrong type of business, or receiving Paycheck Protection Program (PPP) loans. With the latest changes to the eligibility requirements, nearly any employer can qualify, as long as they had between 5 and 500 W-2 employees on the payroll during the pandemic.

The ERTC program was originally launched during the 2020 pandemic and offered rebates of up to $5,000 per employee for keeping staff on the payroll. However, since that time the ERTC program has grown into America’s largest-ever relief program, and experts suggest that there are still billions of dollars left to be claimed.

This new report explains how employers can claim up to $26,000 per employee, with no repayments and no restrictions on how the funds can be spent. The program also has no upper limit on funding, which has allowed some employers to claim upwards of $750,000, using the ERTC Guy application service.

Before beginning an application, the report suggests that each employer take a brief eligibility assessment, to determine if they can qualify, and for how much. This fast assessment, which can be found on the ERTC Guy website, asks only 10 simple questions, requires no proprietary business information, and has no cost or obligation.

The assessment and application service is open to any employer that had fewer than 500 W-2 employees on the payroll during the pandemic, including startups, new businesses founded during the pandemic, and non-profit organizations, such as churches, schools, or clinics. Employers that have already received PPP loans are also encouraged to apply, as any employer that can qualify for PPP loans is also highly likely to qualify for significant ERTC rebates.

More information about the ERTC Guy application service, deadlines, and no-cost eligibility assessment can be found at https://ertcguy.com/employee-retention-tax-credit-extension/

Contact Info:
Name: Scott Hall
Email: Send Email
Organization: ERTC Guy
Address: 60 West 23rd Street Suite 638, New York, NY 10010, United States
Website: https://ertcguy.com/

Source: PressCable

Release ID: 89110605

Should any errors, concerns, or inconsistencies arise from the content provided in this press release that require attention or if a press release needs to be taken down, we kindly request that you immediately contact us at [email protected]. Our efficient team will be at your disposal for timely assistance within 8 hours – taking necessary measures to rectify identified issues or providing guidance on the removal process. We prioritize delivering accurate and reliable information.

More News
No, insulin still doesn’t cost $35
Sep 17, 2026
No, insulin still doesn’t cost $35

Millions of people continue to struggle to pay for their insulin and having their long-term health put at risk. | Spencer Platt/Getty Images A decade ago, insulin became the poster child for America’s out-of-control drug prices. The 2017 death of Alec Smith, who was rationing his insulin before he died, and repeated price hikes for a 100-year-old medication (the patent for which was originally sold for $1 to a university to prevent it from being exploited commercially) sparked widespread outrage that a lifesaving medication could be unaffordable to the people who depend on it to survive. And then politicians actually acted. Starting with a Colorado law passed in 2019, states began passing laws capping the out-of-pocket costs for many people who take insulin; 27 states (plus Washington, DC) now have such a policy. Then in 2022, Congress included a provision in the Inflation Reduction Act that established a $35 per month cap on insulin prescriptions for people on Medicare. Given the national response — drugmakers also made splashy public announcements about reducing the cash price that uninsured people pay — you would be forgiven if you thought this was the one health care cost crisis that the US had genuinely managed to solve. But the diabetes community has a dire warning: It’s not over. Millions of people continue to struggle to pay for their insulin and having their long-term health put at risk because of, in the words of one advocate who put it bluntly, pharmaceutical greed. “There has been so much attention and promise to action around the insulin price crisis. … There has been so much action,” said Shaina Kasper, executive director of T1 International, a global nonprofit that advocates for people with diabetes. “And shockingly, frustratingly, critically, the data from our 2024 survey showed that the rationing rates were worse than ever. Ultimately we’re facing such immense and monstrous corporate greed. … When we put a Band-Aid on one hole, another one’s going to find a way to pop out and keep profits high.” Fixing the insulin crisis will require a multifaceted approach: drug pricing reform, insurance mandates, and possibly even public manufacturing. Out-of-pocket caps, Kasper said, were always a temporary fix for a very broken system. There is still a lot more work to do. Why so many Americans still struggle to afford insulin Both national and local surveys indicate that the policy changes of the past decade have not had the desired effect. A study published last year from researchers at the Yale Diabetes Center found that people treated there were rationing insulin at the same rate in 2024 as they were in 2017; about one in four people reported some rationing due to the cost of the drug in both years. When you added in the people who rationed because of insurance delays or supply limits, more than one in three people — 38 percent — were still having trouble keeping this lifesaving medication on hand in 2024. A 2024 T1 International survey likewise found that nationwide, 34 percent of the Americans who use insulin reported rationing the medicine. (About 8.4 million people in the US rely on insulin to survive.) Dr. Kasia Lipska, an endocrinologist and researcher who treats patients at the Yale Diabetes Center and who co-authored that study, was surprised by their findings. “I was surprised because I’ve been looking at the policy and advocating for policy change; you think things are moving, they should be really improving,” Lipska said. “But if I talked to the nurses and our staff at the Yale Diabetes Center, they told me, ‘Of course they haven’t changed. We’re still hearing these stories.’” How could this be? The explanation is multifaceted, according to Lipska and Kasper.  “There’s just still a lot of holes in one who is covered by various protections and then how they’re covered and how they access this,” Lipska said. “It’s not as simple as just showing up at the pharmacy and asking for your insulin, and the sticker price is there, and that’s what you pay. It’s extremely complicated.” For starters, millions of Americans remain uninsured and have to pay the cash price for drugs. While drugmakers make flashy announcements about helping those people, the process of enrolling for savings cards to get those lower prices can be a nightmare; one congressional investigation found in 2023 that uninsured patients were still paying an average of nearly $100 for insulin despite Eli Lilly’s pledge that its generic product would be available for $25 per vial. Even if you manage to get your discount card, the same investigation found that Lilly introduced several restrictions based on geography and needs, and that the specific insulins that are subject to these voluntary price caps are often out of stock at the pharmacy when people go to fill a prescription (while the more expensive brand name version is consistently available). And then there are the loopholes in those existing federal and state laws. The federal $35 cap applies only to Medicare; the private insurance that covers half the country is excluded. (There have been bills proposed to extend the cap to private coverage, but they have not gone very far in Congress.) The state laws that do exist typically apply only to small-group and individual plans that are subject to state regulations; larger self-funded plans are exempt from state mandates and currently have no enforced limit on out-of-pocket insulin costs. One national estimate found that around 775,000 people who use insulin and had private insurance were protected in 2025 by the caps in states where they’d become law. But more than 1 million people in those states were not, nor were the 2.1 million commercially insured insulin users in states without a cap. Sign up for the Good Medicine newsletter Our political wellness landscape has shifted: new leaders, shady science, contradictory advice, broken trust, and overwhelming systems. How is anyone supposed to make sense of it all? Vox’s senior correspondent Dylan Scott has been on the health beat for a long time, and every week, he’ll wade into sticky debates, answer fair questions, and contextualize what’s happening in American healthcare policy. Sign up here. Even for people who benefit from the mandatory out-of-pocket caps instituted by Medicare and state laws, some of them still struggle to come up with $35 a month, given all of the other price hikes Americans have faced since the pandemic. They may have to navigate a complex process in order to actually receive the promised discount. And while a $35-per-month cap sounds straightforward, in practice, people can still face higher costs. Each individual person requires a unique amount of insulin and, for some of them, they might need two different kinds; the pharmacy may not have the right version and will make substitutions that lead to higher costs. That’s how one of Lipska’s patients ended up paying $140 per month for his insulin — despite being on Medicare. “These things really add up…and frustrate people,” she said, “because what seems like a great idea is not actually how things work on the ground.” The consequence is that, despite all the legislative activity and self-congratulations, millions of Americans are still at risk of serious health problems because they can’t get insulin. The worst-case scenario is what happened to Alec Smith: Somebody is forced to spread their insulin so thin that they put their life is in danger. When diabetics have their blood sugar spike without insulin on hand, they can go into diabetic ketoacidosis, “which literally means your blood is turning into acid,” Kasper said. “I can speak from experience: it feels like you’re dying.” To recover from an episode, they may have to go to the emergency room and end up taking even more insulin while eating in order to get their body back to equilibrium. But even short of an emergency, Kasper said, people who resort to rationing insulin can experience significant side effects. Prolonged high blood sugar due to rationing could lead to serious vision and nerve problems that were supposed to be a thing of the past once insulin became available. Those were the scenarios that lawmakers wanted to prevent as they tried to make insulin more affordable. But they remain a very real threat for too many people. The big idea that could make insulin truly affordable If there’s good news to be found, it’s that the advocacy community is not giving up. They are sounding the alarm about the ongoing affordability crisis and urging Congress to act. But they do worry that the issue has become less urgent: The truly comprehensive mandate for insulin out-of-pocket caps, which is typically introduced every Congress, was delayed this time. “This year, neither bill was introduced for over a year, and it was very concerning,” Kasper said. But they are also placing bets on something much more profound than a price cap: the government itself procuring or even producing insulin and making it available to people at the lowest possible cost.  “This idea that medicines should be for people and not for profit I feel like is really catching,” Kasper said.  Some states are taking baby steps in that direction: Oklahoma passed a bill this year that would offer government funding for private companies that pledge to produce insulin and sell it at a low price.  Others are going bigger. As I reported in 2023, California has launched a program that is eventually intended to lead to government-owned facilities producing insulin to be sold on the cheap, though it will take years until publicly owned production begins. The New York state Senate approved a similar plan this year, although funding for it didn’t make it into the state’s budget. Kasper said that she is optimistic the project will make it into next year’s spending plan, and says a lot of work is currently being done to ensure it happens. In the future, public manufacturing could also help to address the supp

The overlooked factor making everything more expensive
Sep 17, 2026
The overlooked factor making everything more expensive

A sign displays the price of diesel fuel at a Shell gas station in San Diego, California. | Zoe Meyers/Bloomberg via Getty Images This story appeared in Today, Explained, a daily newsletter that helps you understand the most compelling news and stories of the day. Subscribe here. Diesel hit a record $6.40 per gallon this morning, up 73 percent from a year ago. “Not really my problem,” you might be thinking. “I don’t drive a semi or excavator.” But you know who does drive semis and excavators and all the other machines that rely on diesel fuel? The people who farm your food, ferry your online orders, and repave the streets in your neighborhood. All that means the price of diesel trickles down into virtually every segment of the economy. (We’ll get into that a bit more shortly.) Like gas prices, diesel has been rising since the US war with Iran began more than six months ago. But this particular surge was also driven by two incidents in particular: an attack on Saudi Arabia’s East-West pipeline, which has made it costlier and more time-consuming to get oil out, and a Ukrainian drone campaign against Russian oil infrastructure, which has forced major refineries to scale back production. In the aftermath of those attacks, President Donald Trump implored Ukraine to stop targeting refineries. His administration has also relaxed some labor rules for fuel-truck drivers in the hopes of getting more gas and diesel moving. There’s reportedly also talk of invoking the Defense Production Act to scale up America’s refining capacity, or even restricting diesel exports to help drop domestic prices. Not on the solution list, notably: winding down the war in Iran, which kickstarted this whole thing.  Go a little deeper View Link The cost of diesel quietly raises the price of many other goods and services. This is difficult to quantify, but researchers at Brown University estimate that the extra cost paid for diesel between the start of the Iran War and the time I’m drafting this newsletter works out to roughly $374 per US household.  Part of that cost springs from the fact that so many commercial, agricultural, and industrial machines run on diesel fuel. At the risk of sounding like one of my toddler’s “things that go” books, the list includes semis, tractors, excavators, freight trains, buses, cargo ships, and garbage trucks — to say nothing of other machines, like heavy industrial equipment and backup generators. But part of the cost also springs from the fact that demand for diesel fuel is, compared to other goods, pretty inelastic. When the price of regular gas goes up, consumers can cut back on road trips, opt for public transit, or even contemplate an EV purchase. Diesel-dependent industries frequently lack those options, however. As one fuel industry analyst put it in a recent column for the trade publication Oil & Gas 360, a farmer halfway through the harvest — as many are right now — can’t just stop running a combine or tractor because diesel gets pricey.  In other words, it’s difficult for businesses to avoid or offset the higher cost of fuel. And that makes it more likely that they’ll pass on the cost to consumers, even if they’re able to absorb it for a little while. Where will you likely see those added costs first? Your grocery bill, for one. Look for price increases on highly perishable products that travel long distances, like milk, meat, fruits, and vegetables. One link for later ➨ Gossip more ethically. Talking about other people is interesting, common, and — often! — quite fun. But it’s neither very kind, nor particularly moral, to reduce your acquaintances to conversational trading cards. So when you gossip, consider whether your story affords its subject “the concern and respect” you’d expect yourself. If not, try a safer conversational topic: stories about your own experiences.  Before you go… Did you know…that “money dysmorphia” is a real (and common!) cognitive bias? It describes the irrational feeling that money is tight, when you’re actually — on paper — doing just fine.  Today’s trivia: What is the name of the nursery rhyme character referenced in the movie Shrek’s interrogation scene? (You can find this and other brain puzzles in Vox’s daily crossword. Look for the answer in tomorrow’s edition.) Yesterday’s trivia: Yesterday we asked you for a large marine mammal that recently died at a US aquarium. That would be the whale — specifically, the beluga. Three beluga whales died in an eight-day span at Chicago’s Shedd Aquarium in August.

Recommended

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.


Subscribe Now!

About Us

The Journalist Report publishes timely news updates around the clock. We have a group of journalists around the globe to deliver the latest news around so that we can get our users connected.